Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 57 Parameter Total popu- lation Non-tar- get group Target group Distribution Data source Method Utilities rotavirus AGE QALY loss Mild (no medical care) 0.0011 Fixed GP study in Canada 48 50% of estimate for moderate, similar to 11, 17, 31, 49 Moderate (GP visit only) 0.0022 Fixed GP study in Canada 48 Severe (hos- pitalization) 0.0034 Fixed Emergen- cy-depart- ment study in UK 20 Nosocomial Calculated Calculated Calculated RoHo study 14 Based on severity distri- bution, same as in 10 Rotavirus fatal cases Calculated 81.5 minus patient age at rotavirus infection Simulated, assuming LE of 1; 20; 41.3 minus patient’s age with proba- bility of 1/3 each Uni¬form Statistics Netherlands 46 ; Exper t panel 11 For non-target group, based on average LE in the Netherlands. For target group, same as Bruijning et al. 11 Utilities in- tussception QALY loss Uncompli- cated IS 0.0037 Fixed Based on Reyes et al. 37 Complicat- ed IS 0.0111 Fixed Assumption Assuming three times more severe than uncom- plicated IS; see Additional file 1 Healthcare costs rotavirus AGE No medical care €0 Fixed